MUC1 and renal cell carcinoma: One trial evaluating the treatment of advanced RCC with anti-CD3-MUC1 bispecific antibody was withdrawn, and another trial assessing P-MUC1-C-ALLO1 allogeneic CAR-T-cell therapy for advanced or metastatic RCC is in progress.